BMO Capital analyst Matthew Luchini ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst PT Change

Gilead Sciences (GILD), Glympse Bio Report Strategic Collaboration for Use of Biomarker Technology in NASH Clinical DevelopmentOctober 28, 2019 8:05 AM Gilead Sciences (GILD) PT Lowered to $89 at RBC CapitalOctober 25, 2019 6:27 AM